Myriad Genetics Inc (MYGN)

NASD · Healthcare · Diagnostics & Research · USA

Myriad Genetics Inc is a small cap company (market value between $300 million and $2 billion) in the Diagnostics & Research industry.

Myriad Genetics develops and commercializes molecular diagnostic tests that help patients and healthcare providers make medical decisions across oncology, women's health, and mental health. The company's tests analyze genes to assess disease risk, guide treatment selection, and support cancer monitoring. Its customer base includes physicians, patients, and pharmaceutical companies seeking companion diagnostic and biomarker services.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Myriad Genetics Inc stock.

Our verdict on MYGN

Not valued: We cannot value this company yet.

We do not publish a value for this company: not even its current assets cover what it owes.

ETFs with the most weight in MYGN

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Diagnostics & Research

All 44 Diagnostics & Research stocks

Cheaper than MYGN in Diagnostics & Research

23 more in this industry show a wider margin of safety.

Is MYGN undervalued or overvalued?

We do not publish a verdict on MYGN yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of MYGN?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.